Rapid changes in peripheral lymphocyte concentrations during interferon‐free treatment of chronic hepatitis C virus infection
Open Access
- 24 July 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 1 (7) , 586-594
Abstract
Treatment of chronic hepatitis C virus (HCV) infection with direct‐acting antivirals results in a rapid decline in viral load and markers of hepatic inflammation, including serum chemokine (C‐X‐C motif) ligand 10 (CXCL10) concentration, which is followed in most cases by a sustained virologic response. Whether parallel changes of significance occur in the cellular composition of peripheral blood is relatively unknown. We hypothesized that longitudinal characterization of peripheral blood during treatment would provide insight into cellular migration and immune activation, which would have implications for understanding host immunity both before and after HCV treatment and may relate to HCV clearance. We analyzed longitudinal peripheral innate and adaptive immune cell populations by flow cytometry from 95 subjects enrolled in two direct‐acting antiviral clinical trials and examined chemokine receptor expression on T lymphocytes in 43 patients. Within 1‐2 weeks of initiating treatment, significant increases were observed in the concentration of peripheral cluster of differentiation 4–positive (CD4+) and CD8+T lymphocytes but not monocyte or natural killer cells. In tandem with these changes, the percent of both CD4+and CD8+T lymphocytes with an activated phenotype (human leukocyte antigen [HLA] DR+and CD38+) decreased, and T‐lymphocyte surface expression of chemokine (C‐X‐C motif) receptor 3, the chemokine receptor for CXCL10, increased.Conclusion: Rapid changes in peripheral cellular populations occur during direct‐acting antiviral treatment of HCV infection, which could potentially relate to hepatic efflux of tissue lymphocytes due to altered inflammation and chemokine receptor signaling, providing critical insight into the relationship between host immunity and viral clearance during HCV infection. (Hepatology Communications2017;1:586–594)Keywords
Funding Information
- NIAID (K08AI121348)
- NCI
- NIH (HHSN261200800001E)
- Critical Care Medicine Department
This publication has 25 references indexed in Scilit:
- CXCR3 ligands in disease and therapyCytokine & Growth Factor Reviews, 2015
- Restoration of HCV-specific CD8+ T cell function by interferon-free therapyJournal of Hepatology, 2014
- Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcomeJournal of Clinical Investigation, 2014
- T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzeeHepatology, 2014
- Plasma Interleukin-27 (IL-27) Levels Are Not Modulated in Patients with Chronic HIV-1 InfectionPLOS ONE, 2014
- Telaprevir‐based treatment effects on hepatitis C virus in liver and bloodHepatology, 2014
- Hepatic Immune Regulation and Its Involvement in Viral Hepatitis InfectionGastroenterology, 2014
- Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment CharacteristicsJAMA, 2013
- 1 ALTERED HCV SPECIFIC T CELL IMMUNITY VERY EARLY IN INTERFERON FREE HCV DAA THERAPYJournal of Hepatology, 2013
- High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical TrialThe Journal of Infectious Diseases, 2011